Guardian Pharmacy Services, INC 8-K filings

Guardian Pharmacy Services, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and advisory votes on executive compensation and auditor ratification.

Guardian Pharmacy Services announced robust first-quarter 2026 financial results, exceeding prior-year performance and updating full-year guidance with increased Adjusted EBITDA.

Guardian Pharmacy Services completed a $213.9 million public offering of Class A common stock, leading to the loss of its controlled company status and a shift in corporate governance.

Guardian Pharmacy Services reiterates its 2025 financial guidance and provides a preliminary 2026 outlook, projecting adjusted EBITDA growth despite Inflation Reduction Act impacts.

Guardian Pharmacy Services reports strong third-quarter 2025 financial results, including 20% revenue growth and a significant net income turnaround, leading to raised full-year guidance.

Guardian Pharmacy Services, Inc. announced new lock-up agreements with founders, officers, and employees, restricting the sale of approximately 93% of their shares until June 30, 2026.

Guardian Pharmacy Services presented its business strategy and strong financial performance, emphasizing its leadership in the assisted living facility pharmacy market and multi-pronged growth.

Guardian Pharmacy Services reported strong second-quarter 2025 financial results, including double-digit revenue and Adjusted EBITDA growth, leading to raised full-year guidance.

Guardian Pharmacy Services, a leading provider in the Assisted Living Facility (ALF) pharmacy market, showcased its strong financial performance, strategic acquisition model, and innovative technology at its Investor Day on June 18, 2025.

Guardian Pharmacy Services will repurchase shares of Class A common stock from certain holders using proceeds from an underwritten public offering.

Guardian Pharmacy Services held its 2025 Annual Meeting of Stockholders on May 9, 2025, and announced the results of the votes on director elections and the ratification of the independent accounting firm.

Guardian Pharmacy Services announced a 20% year-over-year revenue increase to $329.3 million for Q1 2025, driven by organic growth and acquisitions.

Guardian Pharmacy Services establishes performance metrics tied to revenue, adjusted EBITDA, and geographic expansion for its 2025 executive incentive program.

Guardian Pharmacy Services announces a 20% year-over-year revenue increase for Q4 2024 and a 17% increase for the full year, driven by organic growth and strategic acquisitions.

Guardian Pharmacy Services reports preliminary unaudited financial results for Q4 and full year 2024, exceeding expectations and providing 2025 financial guidance.

Guardian Pharmacy Services approves a 2025 long-term incentive program and 2024 annual cash incentive payouts to its executive officers.

Guardian Pharmacy Services, Inc. has assumed all loan obligations from Guardian Pharmacy, LLC, under an existing loan agreement with Regions Bank.

Guardian Pharmacy Services saw a 20% year-over-year revenue increase in Q3 2024, but reported a net loss due to significant share-based compensation expenses related to its recent IPO.

Guardian Pharmacy Services successfully completed its initial public offering and a series of internal reorganization transactions, including a merger, on September 27, 2024.